Press Releases

Feb 27, 2019

FDA expands indication for Soliqua® 100/33

* Soliqua 100/33 now approved as an add-on to diet and exercise for adults with type 2 diabetes
Feb 25, 2019

Sanofi and Regeneron strongly disagree with verdict upholding three of five Amgen U.S. patent claims relating to PCSK9 antibodies

Praluent® (alirocumab) continues to be available in the U.S.
Feb 25, 2019

Positive results presented from two Phase 3 trials of Dupixent® (dupilumab) in severe chronic rhinosinusitis with nasal polyps
Feb 11, 2019

Sanofi and Regeneron offer Praluent® (alirocumab) at a new reduced U.S. list price

* This is the latest step by the companies to help make Praluent more accessible and affordable for appropriate patients
Feb 7, 2019

Sanofi delivers 2018 business EPS growth of 5.1% at CER
- Video 1
- Photos 4

Show per page

Print
Email page
RSS